UK screening for cystic fibrosis - costs not prohibitive
This article was originally published in Clinica
Executive Summary
Economic arguments against antenatal cystic fibrosis screening are not valid, claims Dr H Cuckle of the Centre for Reproduction Growth and Development at the University of Leeds, UK. Cystic fibrosis screening would not be "much more expensive than other established services, such as maternal serum screening for Down's syndrome," he says (BMJ, December 2nd). The researchers considered the costs of pre- and post-test counselling, parental DNA testing (including both sequential carrier testing and couple carrier testing) and other prenatal diagnostics. Their analysis assumed that all women have two pregnancies, 20% have missing information from previous pregnancies and that the proportion of women changing partners between pregnancies is 20%.
You may also be interested in...
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.